Home › Companies › Cullinan Therapeutics, Inc. › 2025-2026

Cullinan Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Cullinan Therapeutics, Inc.’s Form 8-K, filed 2026-06-16 (Item 5.07 on EDGAR). Page generated 02 October 2026.

4Reported items
184Asset managers
895Fund votes
2026-06-16Meeting date

Proxy season: 2024-2025 2025-2026

Explore Cullinan Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Cullinan Therapeutics, Inc.

These tallies are Cullinan Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-16 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Cullinan Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-16
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Nadim Ahmed	37,519,241	--	--	12,116,759	4,126,430	Majority: yes
Elect Director: Stephen Webster	36,963,086	--	--	12,672,914	4,126,430	Majority: yes
Proposal Three — Advisory Vote on Executive Compensation The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:	48,536,734	1,092,209	7,057	--	4,126,430	Majority: yes

Source: Cullinan Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-16 — read the filing on EDGAR.

How asset managers voted at the Cullinan Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 184 asset managers that disclosed a Cullinan Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Cullinan Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,536,734AGAINST: 1,092,209

Cullinan Therapeutics, Inc.’s own tally for this item (“Proposal Three — Advisory Vote on Executive Compensation The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:”): 48,536,734 for, 1,092,209 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,451,380 outstanding shares: 79% for, 2% against (81% of the company cast a for/against vote).

The 182 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 95%

FOR: 94.7%AGAINST: 1.9%ABSTAIN: 3.3%

Largest asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.” at Cullinan Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Lynx1 Capital Management LP	8,963,500	0	0	For
MPM BioImpact LLC	7,648,268	0	0	For
BVF INC/IL	4,362,044	0	0	For
T. Rowe Price	3,883,866	0	0	For
Vanguard	3,431,574	1	0	For
BlackRock	3,201,658	26,332	0	For
State Street	2,421,607	2,617	0	For
Blue Owl Capital Holdings LP	1,814,764	0	0	For
Kynam Capital Management, LP	0	0	1,808,334	Abstain
RTW INVESTMENTS, LP	1,705,960	0	0	For
Venrock Adviser, LLC	1,379,965	0	0	For
Fidelity	1,364,379	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,354,723	0	0	For
Siren, L.L.C.	1,193,410	0	0	For
Charles Schwab	866,844	0	0	For
Nuveen	755,775	0	0	For
TIAA	741,826	0	0	For
GREAT POINT PARTNERS LLC	600,000	0	0	For
BOONE CAPITAL MANAGEMENT LLC	491,400	0	0	For
Dimensional	480,119	0	0	For
Invesco	0	399,601	0	Against
DEERFIELD MANAGEMENT COMPANY, L.P.	386,169	0	0	For
Affinity Asset Advisors, LLC	361,684	0	0	For
Northern Trust	317,139	2,618	0	For
American Century	0	294,026	0	Against

Showing the 25 largest of 182 asset managers. See all 182 in the interactive database.

2. Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Nadim Ahmed

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%

FOR: 37,519,241WITHHELD: 12,116,759

Cullinan Therapeutics, Inc.’s own tally for this item (“Elect Director: Nadim Ahmed”): 37,519,241 for, 12,116,759 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,451,380 outstanding shares: 61% for, 20% withheld (81% of the company cast a for/withheld vote).

The 50 asset managers below cast 100% of the shares they voted on this item FOR (10,971,822 for, 0 against).

FOR 93%7%

FOR: 10,971,822 (93.0%)ABSTAIN: 826,402 (7.0%)

Largest asset managers voting on “Election of the following individuals nominated to serve as Class III directors, for a three-year term ending ” at Cullinan Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,020,880	4,514	For
T. Rowe Price	1,612,529	0	For
BlackRock	1,600,638	0	For
State Street	1,411,681	3,403	For
Fidelity	1,270,315	0	For
TIAA	741,826	0	For
Charles Schwab	433,275	0	For
Dimensional	0	374,677	Abstain
American Century	0	146,920	Abstain
JPMorgan	135,439	0	For
Equitable	95,565	28,210	For
Invesco	108,711	0	For
Brighthouse	56,617	20,994	For
Bridge Builder Trust	75,506	0	For
Northern Trust	73,173	0	For
Lincoln Financial	48,618	23,561	For
Tema ETF Trust	63,636	0	For
AIG/SunAmerica	0	43,350	Abstain
ProShares	0	40,398	Abstain
Prudential/PGIM	27,800	5,658	For
John Hancock	15,200	13,865	For
Advisor Managed Portfolios	28,255	0	For
MFS	0	26,506	Abstain
Goldman Sachs	23,480	0	For
Global X	23,211	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

3. Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Stephen Webster

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 36,963,086WITHHELD: 12,672,914

Cullinan Therapeutics, Inc.’s own tally for this item (“Elect Director: Stephen Webster”): 36,963,086 for, 12,672,914 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,451,380 outstanding shares: 60% for, 21% withheld (81% of the company cast a for/withheld vote).

The 50 asset managers below cast 100% of the shares they voted on this item FOR (10,844,651 for, 0 against).

FOR 92%8%

FOR: 10,844,651 (91.9%)ABSTAIN: 953,573 (8.1%)

Largest asset managers voting on “Election of the following individuals nominated to serve as Class III directors, for a three-year term ending ” at Cullinan Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,018,677	6,717	For
T. Rowe Price	1,612,529	0	For
BlackRock	1,600,638	0	For
State Street	1,411,681	3,403	For
Fidelity	1,270,315	0	For
TIAA	741,826	0	For
Charles Schwab	433,275	0	For
Dimensional	0	374,677	Abstain
American Century	0	146,920	Abstain
JPMorgan	135,439	0	For
Equitable	95,565	28,210	For
Invesco	108,711	0	For
Brighthouse	56,617	20,994	For
Bridge Builder Trust	23,711	51,795	Abstain
Northern Trust	0	73,173	Abstain
Lincoln Financial	48,618	23,561	For
Tema ETF Trust	63,636	0	For
AIG/SunAmerica	0	43,350	Abstain
ProShares	0	40,398	Abstain
Prudential/PGIM	27,800	5,658	For
John Hancock	15,200	13,865	For
Advisor Managed Portfolios	28,255	0	For
MFS	0	26,506	Abstain
Goldman Sachs	23,480	0	For
Global X	23,211	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

4. Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 50 asset managers below cast 99.9% of the shares they voted on this item FOR (11,798,168 for, 56 against).

FOR: 11,798,168 (100.0%)AGAINST: 56 (0.0%)

Largest asset managers voting on “Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public account” at Cullinan Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	3,025,394	0	For
T. Rowe Price	1,612,529	0	For
BlackRock	1,600,638	0	For
State Street	1,415,028	56	For
Fidelity	1,270,315	0	For
TIAA	741,826	0	For
Charles Schwab	433,275	0	For
Dimensional	374,677	0	For
American Century	146,920	0	For
JPMorgan	135,439	0	For
Equitable	123,775	0	For
Invesco	108,711	0	For
Brighthouse	77,611	0	For
Bridge Builder Trust	75,506	0	For
Northern Trust	73,173	0	For
Lincoln Financial	72,179	0	For
Tema ETF Trust	63,636	0	For
AIG/SunAmerica	43,350	0	For
ProShares	40,398	0	For
Prudential/PGIM	33,458	0	For
John Hancock	29,065	0	For
Advisor Managed Portfolios	28,255	0	For
MFS	26,506	0	For
Goldman Sachs	23,480	0	For
Global X	23,211	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Largest Cullinan Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Cullinan Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 61,451,380 shares outstanding at the time of that meeting.

Top Cullinan Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Lynx1 Capital Management LP	14.59%
2	MPM BioImpact LLC	12.45%
3	BVF INC/IL	7.10%
4	T. Rowe Price	6.32%
5	Vanguard	5.58%
6	BlackRock	5.25%
7	State Street	3.94%
8	Blue Owl Capital Holdings LP	2.95%
9	Kynam Capital Management, LP	2.94%
10	RTW INVESTMENTS, LP	2.78%

Reported Cullinan Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Cullinan Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BVF PARTNERS L P/IL	10.56%	13G
BlackRock	7.24%	13F
Vanguard Group	5.37%	13F
State Street	4.14%	13F
T. Rowe Price	3.30%	13F
Geode Capital	2.23%	13F
Dimensional Fund Advisors	1.47%	13F
Point72	1.47%	13F
Morgan Stanley	1.25%	13F
Two Sigma	0.85%	13F

Percentages above are of 61,451,380 shares outstanding, as reported by Cullinan Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cullinan Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Cullinan Therapeutics, Inc.'s shareholder meeting held 2026-06-16, in the 2025-2026 proxy season, 184 asset managers reported how they voted in their SEC Form N-PX filings, covering 895 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Cullinan Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-16.

Cullinan Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).